These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2190851)

  • 1. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease.
    Mahida YR; Jewell DP
    Digestion; 1990; 45(2):88-92. PubMed ID: 2190851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a slow-release 5'-aminosalicylic acid preparation on disease activity in Crohn's disease.
    Saverymuttu SH; Gupta S; Keshavarzian A; Donovan B; Hodgson HJ
    Digestion; 1986; 33(2):89-91. PubMed ID: 3512352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
    Gastroenterology; 1993 Feb; 104(2):435-9. PubMed ID: 8425685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
    Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL
    Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa.
    Rasmussen SN; Lauritsen K; Tage-Jensen U; Nielsen OH; Bytzer P; Jacobsen O; Ladefoged K; Vilien M; Binder V; Rask-Madsen J
    Scand J Gastroenterol; 1987 Sep; 22(7):877-83. PubMed ID: 3313678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
    Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
    Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.
    Hanauer SB; Strömberg U
    Clin Gastroenterol Hepatol; 2004 May; 2(5):379-88. PubMed ID: 15118975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease.
    Griffiths A; Koletzko S; Sylvester F; Marcon M; Sherman P
    J Pediatr Gastroenterol Nutr; 1993 Aug; 17(2):186-92. PubMed ID: 8229546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
    Hanauer SB; Krawitt EL; Robinson M; Rick GG; Safdi MA
    Am J Gastroenterol; 1993 Sep; 88(9):1343-51. PubMed ID: 8362827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.
    Tremaine WJ; Schroeder KW; Harrison JM; Zinsmeister AR
    J Clin Gastroenterol; 1994 Dec; 19(4):278-82. PubMed ID: 7876505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission.
    Arber N; Odes HS; Fireman Z; Lavie A; Broide E; Bujanover Y; Becker S; Pomerantz I; Moshkowitz M; Patz J
    J Clin Gastroenterol; 1995 Apr; 20(3):203-6. PubMed ID: 7797827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
    Singleton JW; Hanauer S; Robinson M
    Dig Dis Sci; 1995 May; 40(5):931-5. PubMed ID: 7729281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
    Schreiber S; Howaldt S; Raedler A
    Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
    Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Crohn's disease with peroral 5-aminosalicylic acid.
    Rasmussen SN; Binder V; Maier K; Bondesen S; Fischer C; Klotz U; Hansen SH; Hvidberg EF
    Gastroenterology; 1983 Dec; 85(6):1350-3. PubMed ID: 6354827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
    Sutherland LR; Martin F; Bailey RJ; Fedorak RN; Poleski M; Dallaire C; Rossman R; Saibil F; Lariviere L
    Gastroenterology; 1997 Apr; 112(4):1069-77. PubMed ID: 9097988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
    Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R
    N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine.
    Larouche J; Morais J; Picard M; Lambert C; Spénard J; Landriault H; Kennedy G; Poitras P
    Aliment Pharmacol Ther; 1995 Jun; 9(3):315-20. PubMed ID: 7654894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.